Bolodeoku, J., Gbaa, T., Morris, K., & Whitehead, S. (2023). Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic. British Journal of Healthcare and Medical Research, 10(6), 91–102. https://doi.org/10.14738/bjhmr.106.15955